Global Osteopathic Treatment for Patients With NAFLD

NCT03156881 | Unknown

• 1 other identifier: CCOsteopathy
• Study Type: interventional
• Target: 48
• Locations: 0 countries
• Sites: N/A

Brief Summary

Non-alcoholic fatty liver disease is a complex disease that is growing more prominent around the world especially in North America because of high prevalence of overweightness and obesity. There are many factors that are associated with this illness and it does not seem to be the same in every patient. The progression of this disease can with time lead to liver cirrhosis and even primary liver cancer (hepatocellular carcinoma). Currently, the only treatment plan involves diet change and exercise. The goal of this research is to validate that Osteopathy can optimise patient health and to potentially be another option in preventing/reducing progression of this disease. This research is important for the future of Osteopathy to educate the public and other therapists/physicians the benefits this manual therapy has to offer. Previous research has been done and shown that Osteopathy can help patients with low back pain and type two diabetes, by affecting glucose and insulin levels with manipulation of the spine and pancreas. Another study compared one group of obese patients with chronic low back pain that just did specific exercises to another group that were given exercises as well as Osteopathic manual therapy (OMT). Results showed both groups had reduced pain, however only the group with additional OMT showed improved range of motion in the thoracic spine, and showed greater degree of improvement overall for these patients. This study shows how OMT can be effective for individuals with NAFLD for in general these patients are obese and part of their treatment regime is to exercise to lose weight. The researcher could not find any previous research on OMT contributing to weight loss, however according to the Reve Pavilion natural health clinic website (2015), OMT can improve underlying issues such as low back pain, preventing the person to exercise effectively. The researcher also hopes to gain further knowledge of this subject, and to show the benefits of collaborating Osteopathy and Allopathic medicine together to obtain optimal patient care.

Conditions

Non-Alcoholic Fatty Liver Disease

Outcome Measures

Primary Outcomes (3)

• Global osteopathic treatment will improve liver function in patient's with non-alcoholic fatty liver disease.

  Baseline blood work will be taken by Dr.Peltekian prior to commencement of treatments a month beforehand. Four osteopathic treatments will be given within a 6 week period. Then another blood sample will be given by Dr. Peltekian used to compare the differences from the baseline. The researcher will observe any change in liver enzymes, blood count, triacylgylceride levels from the previous blood work and with the control groups. The goal is to see an improvement of liver function from osteopathic treatments.

  6 weeks to complete treatment series. Approximately 12 weeks to receive all relative information to assess.

• Global osteopathic treatment will increase quality of life in patients with non-alcoholic fatty liver disease.

  A Chronic Liver Disease Questionnaire( CLDQ) will be given to both control and treatment groups at the very beginning of the study ( first visit with Dr. Peltekian) and after the treatment series when getting their second blood work. The chronic liver disease questionnaire will be used and measured by Beth Bruce (statistician in Halifax Nova Scotia) using the Analysis of Variance. Data will be analyzed to detect differences over time, between groups and to determine if groups behave differently over time with respect to measures of quality of life. (ANOVA).

  Approximately 12 weeks.

• Global osteopathic treatment will increase readiness to change in patients with Non-Alcohoic Fatty Liver Disease using the URICA questionnaire.

  The University Rhode Island Change Assessment Scale(URICA) will be used to measure each patient's readiness to change ( to improve diet and exercise) in both groups. It will be given twice, a month before and after treatment series to see if osteopathic treatments will have an impact on a person's readiness to change.

  Approximately 12 weeks.

Study Arms (2)

Treatment group

EXPERIMENTAL

The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease. This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series.

Other: Global Osteopathic Treatment

Control Group

NO INTERVENTION

This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.

Interventions

Global Osteopathic Treatment OTHER

The study objectives is to observe a difference and improvement of liver function based on liver enzyme count from blood work after osteopathic treatments. Also to observe an improvement in the patients quality of life after receiving treatment and in their readiness to change. Osteopathy is a type of manual therapy that uses gentle manipulations taking into consideration of the whole person when treating. For example if the liver is being treated, osteopaths look for mobility, to carry out its proper function. However one will also assess its interrelationships that can influence the liver such as its neighbours, articulating structures, example the diaphragm as well as its neurological input from T5-T9 for instance.

Treatment group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Has a confirmed NAFLD diagnosis from Dr. Peltekian.
• Patient is abstaining from alcohol or consuming less than 20 g/day.
• Patient is willing to improve their lifestyle, diet and increase exercise.
• Patient can comprehend English for signing of consent forms.
• Agrees to abstain from any other type of manual therapy besides the researcher's osteopathic treatment during the study period.

You may not qualify if:

• Any other forms of liver disease. --\> The current researcher is interested in a specific liver disease, NAFLD.
• Any tumors/cancer.--\> The researcher does not want to interfere with cancer treatments. As well as the focus of this study is specifically how osteopathy can help patients with NAFLD, not patients with NAFLD plus cancer (more variables to deal with here).
• Patients with any psychiatric issues or dementia.--\> Need proper consent to be able to do the study. Also participants need to be able to remember and compare the difference in how they truly feel before and after treatments on their quality of life that is being measured.
• Aneurysms/thrombosis. --\> The researcher will be doing manual therapy on the body and is planning on working on the fluid/lymph level at times to decrease inflammation. The researcher wants the patient to be safe.
• Any patient abusing alcohol or any illicit drugs. --\> The study is on NON-alcoholic fatty liver disease...not alcoholic.
• Any cardiovascular disease and Type 1 diabetes. --\> Again researcher is trying to focus on the one liver disease NAFLD.
• Extremely high levels of Y glutamyltransferase (GGT): Normal range is: 8 to 65 U/L for adults. --\> This will help to differentiate between NAFLD and alcoholic fatty liver disease.

Sponsors & Collaborators

• Jenna Wilcox: lead

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Condition Hierarchy (Ancestors)

Fatty Liver; Liver Diseases; Digestive System Diseases

Study Officials

• Kevork Peltekian, MD, FRCPC

  Division of Digestive Care & Endoscopy , Department of Medicine , Department of Surgery

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kevork Peltekian, MD, FRCPC

CONTACT

902-473-7833; kevork.peltekian@nshealth.ca

Jenna Wilcox, Student

CONTACT

902-817-6295; jennawilcox2@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Masking Details: Since this study does not involve a sham treatment, the researcher and Dr. Peltekian have decided to have two consent forms. Patients will be assigned a code number and will be divided randomly into treatment or non-treatment groups via Dr. Peltekian opening up sealed envelops made by researcher Jenna Wilcox. Part one of the study will involve Dr. Peltekian asking potential participants consent to be a part of a study measuring " Quality of life and readiness for management of NAFLD". Upon consent, he/she will fill out the two questionnaires and give consent that their routine blood work can be analysed anonymously. During the same time, Dr. Peltekian will open up a sealed envelope revealing a code number and either an invitation to Part 2 of the study or not to invite and to remain as a control participant. By using this method the control group is not informed of the osteopathic research of the study (Part 2), thus reducing bias.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Thesis writer (Completed the 5 year osteopathic program)

Model Details: 24 participants in control group receiving no global osteopathic treatment. Just standard care, baseline blood work every three months, improving their diet and exercise. They will also complete two questionnaires to measure their quality of life and readiness to change. Experimental group will also do the above with additional four osteopathic treatments to compare the differences in quality of life and liver function in both groups.

Study Record Dates

• First Submitted: May 12, 2017
• First Posted: May 17, 2017
• Study Start: July 1, 2017
• Primary Completion: November 1, 2017
• Study Completion: May 1, 2018
• Last Updated: May 17, 2017

Record last verified: 2017-05